表紙
市場調査レポート

CEL-SCI Corporation - 製品パイプラインレビュー

CEL-SCI Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 240914
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
CEL-SCI Corporation - 製品パイプラインレビュー CEL-SCI Corporation - Product Pipeline Review - 2015
出版日: 2015年04月29日 ページ情報: 英文 40 Pages
概要

CEL-SCI Corporationは米国に本社をおくバイオテクノロジー企業で、癌および感染症に対抗する免疫システムを活性化する技術の開発に注力しています。免疫療法用医薬品の研究開発を進めており、癌、ヒトパピローマウィルス(HPV)に対しMultikine (白血球インターロイキン注射薬)の治験を行っています。

当レポートでは、CEL-SCI Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

CEL-SCI Corporationの基本情報

  • CEL-SCI Corporationの概要
  • 主要情報
  • 企業情報

CEL-SCI Corporation:R&Dの概要

  • 主な治療範囲

CEL-SCI Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

CEL-SCI Corporation:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

CEL-SCI Corporation:薬剤プロファイル

  • Leukocyte Interleukin
  • LEAPS-H1N1-DC
  • CEL-1000
  • CEL-2000
  • Vaccine for Breast Cancer

CEL-SCI Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

CEL-SCI Corporation:最新のパイプライン情報

CEL-SCI Corporation:開発休止中のプロジェクト

CEL-SCI Corporation:企業理念

CEL-SCI Corporation:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07022CDB

Summary

Global Markets Direct's, 'CEL-SCI Corporation - Product Pipeline Review - 2015', provides an overview of the CEL-SCI Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CEL-SCI Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CEL-SCI Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CEL-SCI Corporation's pipeline products

Reasons to buy

  • Evaluate CEL-SCI Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CEL-SCI Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CEL-SCI Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CEL-SCI Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CEL-SCI Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CEL-SCI Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CEL-SCI Corporation Snapshot
    • CEL-SCI Corporation Overview
    • Key Information
    • Key Facts
  • CEL-SCI Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • CEL-SCI Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CEL-SCI Corporation - Pipeline Products Glance
    • CEL-SCI Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • CEL-SCI Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • CEL-SCI Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • CEL-SCI Corporation - Drug Profiles
    • Leukocyte Interleukin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEAPS-H1N1-DC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEL-1000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEL-2000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CEL-SCI Corporation - Pipeline Analysis
    • CEL-SCI Corporation - Pipeline Products by Target
    • CEL-SCI Corporation - Pipeline Products by Route of Administration
    • CEL-SCI Corporation - Pipeline Products by Molecule Type
    • CEL-SCI Corporation - Pipeline Products by Mechanism of Action
  • CEL-SCI Corporation - Recent Pipeline Updates
  • CEL-SCI Corporation - Dormant Projects
  • CEL-SCI Corporation - Dormant Projects
  • CEL-SCI Corporation - Company Statement
  • CEL-SCI Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CEL-SCI Corporation, Key Information
  • CEL-SCI Corporation, Key Facts
  • CEL-SCI Corporation - Pipeline by Indication, 2015
  • CEL-SCI Corporation - Pipeline by Stage of Development, 2015
  • CEL-SCI Corporation - Monotherapy Products in Pipeline, 2015
  • CEL-SCI Corporation - Phase III, 2015
  • CEL-SCI Corporation - Phase I, 2015
  • CEL-SCI Corporation - Preclinical, 2015
  • CEL-SCI Corporation - Pipeline by Target, 2015
  • CEL-SCI Corporation - Pipeline by Route of Administration, 2015
  • CEL-SCI Corporation - Pipeline by Molecule Type, 2015
  • CEL-SCI Corporation - Pipeline Products by Mechanism of Action, 2015
  • CEL-SCI Corporation - Recent Pipeline Updates, 2015
  • CEL-SCI Corporation - Dormant Developmental Projects,2015
  • CEL-SCI Corporation, Subsidiaries

List of Figures

  • CEL-SCI Corporation - Pipeline by Top 10 Indication, 2015
  • CEL-SCI Corporation - Pipeline by Stage of Development, 2015
  • CEL-SCI Corporation - Monotherapy Products in Pipeline, 2015
  • CEL-SCI Corporation - Pipeline by Top 10 Target, 2015
  • CEL-SCI Corporation - Pipeline by Top 10 Route of Administration, 2015
  • CEL-SCI Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top